ImmuCell Corporation (ICCC)

Market Cap	40.28M
Revenue (ttm)	16.01M
Net Income (ttm)	-5.32M
Shares Out	7.75M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,954
Open	5.00
Previous Close	5.00
Day's Range	5.00 - 5.20
52-Week Range	4.26 - 9.61
Beta	0.66
Analysts	n/a
Price Target	n/a
Earnings Date	May 11, 2023

About ICCC

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 1987
• Employees: 67
• Stock Exchange: NASDAQ
• Ticker Symbol: ICCC

Financial Performance

In 2022, ImmuCell's revenue was $18.57 million, a decrease of -3.51% compared to the previous year's $19.24 million. Losses were -$2.49 million, 3085.3% more than in 2021.